Best OncLive® On Air Podcasts (2025)

1
S13 Ep9: Multidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCM 12:53

19h ago12:53

12:53

In today’s episode, we had the pleasure of speaking with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026 president-elect of ASCO. Dr Mittendorf is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and the vice chair for research in the Department of Surgery at the Brigham and Women's Hospital; co-leader of the Breast Program and dire…

1
S13 Ep8: Oncology PER® Spectives: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma 54:11

22h ago54:11

54:11

This Oncology PER®Spectives™ podcast examines the recent advancements in the treatment landscape for advanced melanoma.In this activity, expertsYana Najjar, MD; Rahul A. Sheth, MD, FSIR; and Douglas Johnson, MD, MSCI, discuss the challenges of immune checkpoint inhibitor resistance and the practical strategies for overcoming this by using direct in…

1
S13 Ep7: Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD 9:09

5d ago9:09

9:09

Drs Park and Malla began by talking through the clinical utility of ctDNA in patients with stage II and III colon cancer. Dr Malla referenced the DYNAMIC (ACTRN12615000381583) and observational BESPOKE CRC (NCT04264702) trials, noting that ctDNA serves as a prognostic biomarker for recurrence and is increasingly used to guide post-surgical surveill…

1
S13 Ep6: FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD 7:48

6d ago7:48

7:48

In today’s episode, we spoke with Matthew Galsky, MD, about the FDA approval of neoadjuvant durvalumab (Imfinzi) plus gemcitabine and cisplatin followed by adjuvant durvalumab monotherapy after radical cystectomy for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). Dr Galsky is a professor of medicine (hematology and medi…

1
S13 Ep5: Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD 8:56

8d ago8:56

8:56

In this week’s episode of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Paul Hanona, MD, to give advice to up-and-coming oncology content creators. Dr Hanona is a content creator under the handle @doctordiscover. In the final part of this 3-part se…

1
S13 Ep4: Eltrombopag Biosimilar Improves Accessibility for Immune Thrombocytopenia & Aplastic Anemia: With Kanwarpal S. Kahlon, MD 8:24

12d ago8:24

8:24

In today’s episode, supported by Camber Pharmaceuticals, we spoke with Kanwarpal S. Kahlon, MD, an associate clinical professor of medicine at the UCLA School of Medicine. In our exclusive interview, Dr Kahlon discussed the significance of the commercial availability of the generic, AB-rated formulations of eltrombopag (Promacta), a bioequivalent m…

1
S13 Ep3: Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD 12:59

15d ago12:59

12:59

In today’s episode, supported by Azurity Pharmaceuticals, we spoke with Michael J. Mauro, MD, about treatment adherence with nilotinib (Tasigna/Danziten) in patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML). Dr Mauro is an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York. In our ex…

1
S13 Ep2: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer 49:30

15d ago49:30

49:30

This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with …

1
S13 Ep1: Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott 24:09

19d ago24:09

24:09

In today’s episode, we spoke with Shubham Pant, MD, MBBS, and Professor Timothy Elliott, about ongoing research with cancer vaccines. Dr Pant is a professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. Dr Elliott is the Kidani Professor of …

1
S12 Ep50: Optimizing Today and Looking to Tomorrow in Metastatic CRPC - Homing in on EZH2 43:33

20d ago43:33

43:33

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educat…

1
S12 Ep49: MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD 12:54

22d ago12:54

12:54

In today’s episode, supported by SpringWorks Therapeutics, we spoke with Christopher L. Moertel, MD, about the evolution of treatments for neurofibromatosis type 1 (NF1)–associated plexiform neurofibromas (PN). Dr Moertel is a professor and the Pediatric Neuro-Oncology Fellowship Program director in the Division of Pediatric Hematology/Oncology, a …

1
S12 Ep48: Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation 1:17:00

22d ago1:17:00

1:17:00

This featured podcast includes a data review and candid conversation with 4 experts on challenges in the current treatment paradigm for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) due to endocrine resistance. This session occurred during a satellite symposium held in conjunction with the 42nd Annual Miami Brea…

1
S12 Ep47: Early-Phase RAS Inhibitor Research Sparks Interest in NSCLC: With Kathryn C. Arbour, MD 9:43

26d ago9:43

9:43

In today’s episode, supported by Revolution Medicines, we spoke with Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, about 2 important abstracts presented at the 2024 AACR Annual Meeting that explore novel RAS-targeted approaches in non–small cell lung cancer (NSCLC). Our discuss…

1
S12 Ep46: Managing Side Effects and Fertility for Premenopausal Patients with Advanced HR+ Breast Cancer 1:04:27

27d ago1:04:27

1:04:27

This expert podcast includes an engaging discussion among 3 experts on fertility care of patients with breast cancer. This program is designed to help clinicians better recognize and take steps to discuss fertility options in premenopausal patients with hormone receptor-positive (HR+) breast cancer to facilitate care for those women who wish to pre…

1
S12 Ep45: RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA 10:56

29d ago10:56

10:56

In today’s episode, supported by Replimune, we had the pleasure of speaking with Anna C. Pavlick, BSN, MSc, DO, MBA, about the use of RP1 plus nivolumab (Opdivo) for the treatment of patients with advanced melanoma. Dr Pavlick is a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine in New York, New York…

1
S12 Ep44: Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH 12:33

1M ago12:33

12:33

In today’s episode, we had the pleasure of speaking with Jacob Moyer, BS, and Mark Tyson II, MD, MPH, about a real-world study investigating nadofaragene firadenovec in patients with BCG-unresponsive NMIBC. Moyer is a graduate researcher at Mayo Clinic in Scottsdale, Arizona. Tyson is a urologic oncologist and an associate professor of urology at t…

1
S12 Ep43: Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD 19:32

1M ago19:32

19:32

In today’s episode, we had the pleasure of speaking with Nicole Lamanna, MD, about patient selection considerations for the use of pirtobrutinib (Jaypirca) in the management of chronic lymphocytic leukemia (CLL). Dr Lamanna is a hematologic oncologist at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irvi…

1
S12 Ep42: Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD 7:28

1M ago7:28

7:28

In today’s episode, we had the pleasure of speaking with Daniel P. Petrylak, MD, about Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in metastatic castration-resistant prostate cancer (mCRPC). Dr Petrylak is a professor of medicine (medical oncology) and urology, as well as the chief of Genitourinary Oncology, at Yale School of Medicine and Smil…

1
S12 Ep41: Oncodetect MRD Detection Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD 13:53

1M ago13:53

13:53

In today’s episode, supported by Exact Sciences, we had the pleasure of speaking with Eric Christenson, MD, about the Oncodetect test, which is available for use in molecular residual disease detection in patients with solid tumors. Dr Christenson is an assistant professor of oncology at the Johns Hopkins School of Medicine in Baltimore, Maryland. …

1
S12 Ep40: Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD 9:12

1M ago9:12

9:12

In this week’s episode of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Paul Hanona, MD, to give advice to up-and-coming oncology content creators. Dr Hanona is the chief Hematology Oncology Fellow at Beaumont Health in Royal Oak, Michigan. He is a…

1
S12 Ep39: Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD 12:25

2M ago12:25

12:25

In this week’s episode of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, sat down with Paul Hanona, MD, to talk about their shared passion for using social media to share accessible information with oncologists and patients alike. Dr Hanona is the chief Hematology …

1
S12 Ep38: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC 44:04

2M ago44:04

44:04

This PER® Spectives™ featured podcast reviews the 22nd Annual Winter Lung Cancer Conference® held in January/February 2025. Multiple successive generations of ALK inhibitors have provided increasing benefits as first-line treatment for the thousands of patients with non-small cell lung cancer (NSCLC) that harbors rearrangements or mutations in the …

1
S12 Ep37: Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD 5:28

2M ago5:28

5:28

In this week’s episode of MedNews Week’s Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, concluded a 3-part series with Vadim Koshkin, MD, an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, S…

1
S12 Ep36: Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD 23:28

2M ago23:28

23:28

In today’s episode, we sat down with Liliana Bustamante, MD, and Jessica Stine, MD, to discuss their experiences as women in oncology. Dr Bustamante is a medical oncologist and hematologist at Florida Cancer Specialists & Research Institute in Tampa. Dr Stine is the medical director of Gynecologic Oncology at Florida Cancer Specialists & Research I…

1
S12 Ep35: Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD 13:06

2M ago13:06

13:06

In this week's episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, sat down with Vadim Koshkin, MD, an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco (UCS…

1
S12 Ep34: AR Pathway Inhibition Refines Prostate Cancer Treatment Strategies: With Neal Shore, MD, FACS 8:16

2M ago8:16

8:16

In today’s episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about prostate cancer management and the use of androgen receptor (AR)–directed therapies. Dr Shore is the medical director for the Carolina Urologic Research Center in Myrtle Beach, South Carolina. In our exclusive interview, we sat down with Dr Shore during the 2025 Br…

1
S12 Ep33: Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD 18:19

2M ago18:19

18:19

In today’s episode, supported by EMD Serono, we had the pleasure of speaking with Chandler Park, MD, about the first-line treatment of patients with bladder cancer. Dr Park is a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky. In our exclusive interview, Dr Park discussed the core regimens in the current frontline bladder …

1
S12 Ep32: ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD 10:30

2M ago10:30

10:30

In this week's episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, sat down with Vadim Koshkin, MD, an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco (UCS…

1
S12 Ep31: Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD ... 13:54

2M ago13:54

13:54

In today’s episode, we invited experts from across oncology specialties to discuss the long-term effects of the COVID-19 pandemic—the onset of which occurred 5 years ago. Our guests shared how the pandemic's lingering effects continue to shape patient care. We heard from: Ramez N. Eskander, MD, a gynecologic oncologist and assistant professor of ob…

1
S12 Ep30: Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD 15:16

2M ago15:16

15:16

In today’s episode, OncLive teamed up with CURE to present a discussion with David A. Braun, MD, PhD, about his research on determinants of response to immune checkpoint inhibition (ICI) in patients with renal cell carcinoma (RCC). Dr Braun is an assistant professor of medicine (medical oncology), the Louis Goodman and Alfred Gilman Yale Scholar, a…

1
S12 Ep29: Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc 20:48

2M ago20:48

20:48

In this week's episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, spoke with Ann S. LaCasce, MD, MMSc, an associate professor of medicine and a lymphoma specialist at Dana-Farber Cancer Institute in Boston, Massachusetts and Director of the Dana-Farber/Mass …

1
S12 Ep28: Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD 11:22

2M ago11:22

11:22

In today’s episode, supported by Summit Therapeutics, we had the pleasure of speaking with Xiuning Le, MD, PhD, about the use of ivonescimab (SMT112) in patients with PD-L1–positive non–small cell lung cancer (NSCLC). Dr Le is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at…

1
S12 Ep28: Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD 9:57

2M ago9:57

9:57

In today’s episode, supported by Takeda, we had the pleasure of speaking with Ibrahim T. Aldoss, MD, and Elias Jabbour, MD, about the use of ponatinib (Iclusig) monotherapy after combination chemotherapy in patients with newly diagnosed Philadelphia chromosome–positive (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Aldoss is an associate prof…

1
S12 Ep27: Venetoclax Plus Pegcrisantaspase Induces Remissions in R/R AML: With Ashkan Emadi, MD, PhD 19:58

3M ago19:58

19:58

Dr Emadi discussed how the combination of venetoclax (Venclexta) plus pegcrisantaspase induced complete remissions in heavily pretreated patients with relapsed/refractory acute myeloid leukemia, including in those with prior exposure to venetoclax. He detailed data on the combination from a phase 1 study published in Blood, the significance of the …

1
S12 Ep26: FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD 9:30

3M ago9:30

9:30

In our exclusive interview, Dr Uboha discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 RATIONALE-306 trial (NCT03783442), and considerations for integrating this agent into the ESCC treatment paradigm.By OncLive® On Air

1
S12 Ep25: Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD 23:04

3M ago23:04

23:04

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, spoke with Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program at Fred Hutchinson Cancer Center and a professor of medicine at the University of Washington School of Medici…

1
S12 Ep24: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes 54:09

3M ago54:09

54:09

This featured podcast includes a discussion with 3 experts on best practices in the care of patients with chronic lymphocytic leukemia (CLL), the most common hematologic leukemia diagnosed among adults worldwide. Treatment for CLL continues to evolve rapidly. Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of …

1
S12 Ep23: Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc 5:27

3M ago5:27

5:27

Dr Kaklamani discusses the mechanism of action of inavolisib, the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm, and considerations for early biomarker testing in patients with breast cancer.By OncLive® On Air

1
S12 Ep22: FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD 7:48

3M ago7:48

7:48

Dr Tap discusses the significance of the FDA approval of vimseltinib for symptomatic TGCT, in which surgical resection may worsen functional limitation or cause severe morbidity. He also discussed key efficacy and safety data from the pivotal phase 3 MOTION trial and the increasingly important role that multidisciplinary collaboration will play as …

1
S12 Ep21: Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma 30:09

3M ago30:09

30:09

This featured podcast brings together 2 experts to discuss the care of patients with epithelioid sarcoma.By OncLive® On Air

1
S12 Ep20: FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD 7:39

3M ago7:39

7:39

Dr Fakih discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial (NCT05198934), and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.By OncLive® On Air

1
S12 Ep19: FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO 7:20

3M ago7:20

7:20

In today’s episode, we had the pleasure of speaking with Aditya Bardia, MD, MPH, FASCO, about the FDA approval of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of adult patients with unresectable or metastatic, hormone receptor–positive, HER2-low or -ultralow breast cancer, as determined by an FDA-approved test, that has progre…

1
S12 Ep18: Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD 20:33

3M ago20:33

20:33

In this episode of Oncology Unplugged, a podcast series from OncLive and MedNews Week, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD, to talk about a pilot trial investigating neoadjuvant accelerated methotrexate, vinblastine,…

1
S12 Ep17: Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO 11:49

3M ago11:49

11:49

In today’s episode, we had the pleasure of speaking with Rachna Shroff, MD, MS, FASCO, about the phase 3 SWOG S1815 trial (NCT03768414) evaluating the addition of nab-paclitaxel (Abraxane) to gemcitabine and cisplatin in patients with newly diagnosed, advanced biliary tract cancer. Dr Shroff of the interim clinical affairs director, the associate d…

1
S12 Ep16: DA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD 11:18

3M ago11:18

11:18

Dr Moertel discussed the significance of this approval, key efficacy and safety data from the phase 2 ReNeu trial (NCT03962543), and considerations for integrating mirdametinib into clinical practice for patients with NF1-associated PN.By OncLive® On Air

1
S12 Ep15: Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP 14:58

4M ago14:58

14:58

In today’s episode, supported by Genentech, we had the pleasure of speaking with Komal Jhaveri, MD, FACP, about the clinical use of inavolisib (Itovebi) for patients with hormone receptor (HR)–positive, PIK3CA-mutated, locally advanced or metastatic breast cancer. Dr Jhaveri is section head of the Endocrine Therapy Research Program, clinical direct…

1
S12 Ep14: FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO 6:33

4M ago6:33

6:33

In our exclusive interview, Dr Bardia discussed the significance of this approval, pivotal findings from the phase 3 TROPION-Breast01 trial (NCT05104866), the clinical relevance of being able to improve progression-free survival and quality of life with Dato-DXd compared with standard chemotherapy, and key considerations for sequencing antibody-dru…

1
S12 Ep13: Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD 30:35

4M ago30:35

30:35

In today’s episode, supported by Takeda, we had the pleasure of speaking with Mark B. Geyer, MD, and Elias Jabbour, MD, about updates in the management of Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Geyer is the Adolescent and Young Adult Program leader and the Adult Lymphoblastic Leukemia Program leader in the Leuk…

1
S12 Ep12: Advances in RAS-Mutant PDAC Management Emphasize the Importance of Biomarker Testing: With Heinz-Josef Lenz, MD 9:26

4M ago9:26

9:26

In today’s episode, supported by Revolution Medicines, we had the pleasure of speaking with Heinz-Josef Lenz, MD, about RAS mutations in pancreatic ductal adenocarcinoma (PDAC). Dr Lenz is a professor of medicine at the Keck School of Medicine of the University of Southern California (USC), as well as the J. Terrence Lanni Chair in Gastrointestinal…

1
S12 Ep10: Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD 5:49

4M ago5:49

5:49

In today’s episode, supported by Ascentage Pharma, we had the pleasure of speaking with Elias Jabbour, MD, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Dr Jabbour discussed the 1.5-year follow-up data from a phase 1b trial (N…

Podcasts Worth a Listen

OncLive® On Air Podcasts

Podcasts Worth a Listen